Haleon PLC Sponsored ADR $HLN Shares Bought by Hantz Financial Services Inc.

Hantz Financial Services Inc. raised its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 11.1% during the 4th quarter, Holdings Channel reports. The firm owned 698,267 shares of the company’s stock after buying an additional 69,818 shares during the quarter. Hantz Financial Services Inc.’s holdings in Haleon were worth $7,059,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HLN. Atlantic Union Bankshares Corp grew its holdings in Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after purchasing an additional 2,758 shares during the period. Stance Capital LLC acquired a new stake in Haleon in the third quarter valued at approximately $34,000. Geneos Wealth Management Inc. grew its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in Haleon by 428.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after purchasing an additional 5,124 shares during the period. Finally, Assetmark Inc. grew its holdings in Haleon by 26.6% in the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock valued at $60,000 after purchasing an additional 1,252 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Finally, Argus raised Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Haleon presently has a consensus rating of “Moderate Buy” and an average target price of $13.40.

Haleon Stock Up 0.2%

NYSE HLN opened at $9.30 on Tuesday. The business has a fifty day moving average price of $9.63 and a 200 day moving average price of $9.97. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The company has a market cap of $41.30 billion, a P/E ratio of 23.86, a P/E/G ratio of 2.12 and a beta of 0.15.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The firm had revenue of $3.65 billion during the quarter. Research analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Haleon Dividend Announcement

The business also recently declared a dividend, which was paid on Thursday, May 14th. Stockholders of record on Friday, April 10th were given a $0.1307 dividend. The ex-dividend date was Friday, April 10th. This represents a dividend yield of 266.0%. Haleon’s dividend payout ratio is 64.10%.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.